In the news
Press releases
Touchlight Aquaculture believes it can yield next generation of fish vaccines
7th January, 2022
Established in 2020, Touchlight Aquaculture is fostering a series of DNA vaccines for various diseases in salmon. IHS Markit’s head of animal health Joseph Harvey spoke to one of the firm’s parent businesses to find out more about its pipeline progress to date and how it can contribute to aquaculture’s DNA revolution. Touchlight Aquaculture hopes […]
Read more
Stonehaven Incubate launches new company aiming to tackle canine osteoarthritis
5th May, 2021
Stonehaven Incubate has partnered with human health player Regenosine to launch Vetosine, a new company that will develop and commercialize a first-in-class disease modifying osteoarthritis drug (DMOAD) for animals, with an initial focus on dogs. “Vetosine’s proprietary adenosine-based treatment will be a real game changer for the industry,” said Charlie Dawson, Venture Partner at Stonehaven […]
Read more
6th April, 2021
Stonehaven Incubate has closed a further capital raising having secured significant investment from existing shareholder Elanco, and from Argenta, a leading animal health CRO and CMO. The funding will allow Stonehaven Incubate to expand investments into new portfolio companies and provide capital to potentially further invest in its existing five start-up businesses. Jarne Elleholm, CEO […]
Read more
Stonehaven Incubate appoints Jarne Elleholm as new CEO
1st March, 2021
Andermatt, Switzerland (1 March 2021) – Stonehaven Incubate AG has appointed former Copenhagen Life Science Advisors Managing Partner, Jarne Elleholm as its new full time CEO with effect from 1 March. He replaces founding Stonehaven Incubate CEO and animal health executive, Dr Mark Heffernan, who will remain on the board of directors. The dedicated animal […]
Read more
2nd November, 2020
London/England (2 November) – Stonehaven Incubate AG and Agile Sciences Inc have completed initial studies validating the safety and efficacy of Agile’s small molecules , leading to the formation of a new company, Anifera Limited. Anifera will have the exclusive rights to manufacture, develop and commercialise the family of molecules in all applications in animal […]
Read more
Touchlight Genetics and Stonehaven Incubate form Touchlight Aquaculture
29th September, 2020
The new company will allow accelerated commercial scalability of DNA vaccines in the aquaculture industry London, England / Andermatt, Switzerland (Date) – Touchlight Genetics LLC and Stonehaven Incubate AG have formed a new joint venture company, Touchlight Aquaculture LLC, to combine expertise, intellectual property and platform technology. The new company will utilize Touchlight Genetics’ innovative […]
Read more
Anizome® announces appointment of Dr. Bénédicte Flambard as Chairperson
13th July, 2020
ANIZOME LLC, a company dedicated to the commercial application of microbiome science in animal health by leveraging insights from the role of the microbiome in human healthcare, has announced the appointment of Dr. Bénédicte Flambard as the Chairperson of its Board of Directors. Dr. Flambard specialises in heading the innovation and development of commercial strategies […]
Read more
Stonehaven Incubate creates unique collaboration to boost animal health through wearable technology
25th February, 2020
Stonehaven Incubate has teamed up with Sports Performance Tracking (SPT) and veterinary pain specialist, Dr. B Duncan X Lascelles – all leaders in their respective fields – to create a new venture that will commercialise sensor technology to improve animal health. AniV8 (pronounced An-i-vate) is designed to become the leading developer of clinical sensor technology […]
Read more
Stonehaven Incubate appoints Charlie Dawson as Venture Partner
31st January, 2020
Charlie Dawson has been appointed as Venture Partner at Stonehaven Incubate, adding to the established team, to identify new opportunities for animal health spin-outs and support partners with opportunity evaluation and growth. He has over 20 years of experience in strategy, marketing and leadership in the life sciences sector. Prior to joining Stonehaven Incubate, he […]
Read more
Elanco Animal Health supports Stonehaven Incubate
26th August, 2019
26 August, Kansas: Stonehaven Incubate, a business incubator that brings disruptive human health technologies to the animal sector, has received capital backing from the global animal health company Elanco Animal Health Incorporated (“Elanco”). The capital will enable Stonehaven Incubate to advance new and existing opportunities, and expand its global team. Elanco’s investment accompanies additional participation […]
Read more
Stonehaven Incubate further invests in its team
29th July, 2019
Stonehaven Incubate has appointed Dr Gwynneth Thomas as Investment Manager based in London. Dr Thomas has extensive scientific and commercial experience in the areas of pathology, genomics, digital health, medical device and diagnostics. Dr Mark Heffernan, CEO of Stonehaven Incubate, said: “Gwynneth has spent her career at the intersection of business and science, gaining significant […]
Read more
Stonehaven Incubate appoints new chairman
18th June, 2019
Stonehaven Incubate has announced the appointment of Dr. Fabian Kausche as its new Chairman. Dr. Kausche is a seasoned executive with over 25 years’ experience in the animal and consumer health industries. Most recently, he was SVP, Global Head of R&D for Boehringer Ingelheim Animal Health from 2017 to 2018. Between 2008 and 2016, he […]
Read more
Stonehaven Incubate celebrates first birthday with new friends
27th March, 2019
Stonehaven Incubate is celebrating its first birthday and already has three active on-going collaborations to drive improvements in animal health. “We have evaluated over 33 opportunities in the past 12 months, we’ve actively moved forward on three and we have a number in negotiation, with memorandums of understanding and option agreements underway. We target at […]
Read more22nd February, 2019
Stonehaven Incubate and US-based biopharmaceutical company Agile Sciences, Inc. have signed a collaboration agreement for the development of innovative veterinary pharmaceutical therapeutic and prophylactic treatments. Agile’s technology consists of a family of small molecules that uniquely disable bacterial protection mechanisms. When combined with antibiotics, including antibiotics which have been rendered ineffective due to resistance issues, […]
Read moreStonehaven Incubate and Lysando sign agreement to develop new anti-microbials for companion animals
18th December, 2018
A new collaboration between Stonehaven Incubate and anti-microbial protein specialist Lysando aims to develop ground-breaking therapies for companion animal infections. The companies have agreed to conduct proof-of-concept trials for new topical treatments based on Artilysin® anti-microbials, an innovative technology platform developed by Lysando. Once the initial studies have been successfully completed, the partners have agreed […]
Read more
Stonehaven Incubate strengthens team
20th November, 2018
Stonehaven Incubate has appointed Dr Ellie Virtue as Investment Manager. Dr Virtue is a scientific and commercial professional with experience in start-up human and veterinary biotech companies. She has provided consulting and business services to early-stage human, veterinary and agtech companies where her roles have included a wide range of functions including operations, commercialization, R&D […]
Read more
Stonehaven Incubate closes initial capital raising
13th November, 2018
Stonehaven Incubate has closed capital raising for its first investment, after securing the backing of a group of global life science and animal health investors. Launched earlier this year as an innovative vehicle for human health companies to expand into the animal health sector, the funding will enable the company to invest directly in a […]
Read more
Anizome™ launches microbiome discovery platform for animal health and nutrition
23rd May, 2018
ANIZOME™, the first company to offer a commercial therapeutic microbiome discovery platform dedicated to animal health and nutrition, is launched today. The collection of microorganisms that inhabit the bodies of humans and animals have been studied extensively in recent years and play an important role in maintaining host health. While over $1 billion has been […]
Read more
Stonehaven Incubate appoints Dr Mark Heffernan as CEO
7th March, 2018
Dr Mark Heffernan has been appointed the Chief Executive Officer of Stonehaven Incubate. The company, which officially launches this month at the Human Biotech and Animal Health Summit in Boston, has been formed as a vehicle for human biotechnology companies to expand their innovations into the animal health sector. Prior to joining Stonehaven Incubate, Dr […]
Read moreStonehaven Incubate launches at Boston Summit: Dr Mark Heffernan appointed CEO
7th March, 2018
Stonehaven Incubate will be officially launched at the Human Biotech and Animal Health Business Partnering Summit in Boston on 12th March, when the company’s newly appointed CEO, Dr Mark Heffernan, will be presenting this exciting new venture while the company also sponsors a networking drinks reception at the Hilton Dedham Hotel. Stonehaven Incubate is a […]
Read more